Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300630 | 0.79 | ALDH1A1 (0.47) | GPR35MAPTNPC1RAB9AKMT2A | |
| SCHEMBL14271783 | 0.74 | MAPK1 (0.48) | MAPTKMT2AMEN1PKM | |
| SCHEMBL14341595 | 0.73 | METAP1 (0.40) | — | |
| SCHEMBL21875055 | 0.69 | KMT2A (0.45) | MAPTDAORAB9AKMT2AMEN1 | |
| SCHEMBL23927258 | 0.68 | KMT2A (0.33) | DAOKMT2A | |
| SCHEMBL18047948 | 0.68 | PTPN1 (0.41) | GPR35MAPTKMT2A | |
| SCHEMBL5489140 | 0.67 | DAO (0.45) | GPR35DAO | |
| SCHEMBL23927261 | 0.66 | CYP2A6 (0.32) | MAPTKMT2AMEN1 | |
| SCHEMBL23927233 | 0.66 | CYP2A6 (0.31) | KMT2A | |
| SCHEMBL5484511 | 0.65 | DAO (0.43) | GPR35DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307174-B2 | Process and intermediates for the preparation of thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-20050272938-A1 | Process and intermediates for the preparation of thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1549653-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THIENOPYRROLE DERIVATIVES | Astrazeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031193-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF THIENOPYRROLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272938-A1 | Process and intermediates for the preparation of thienopyrrole derivatives | POR, CYP3A4, CYP2C19 | GPR35 2659/4885MAPT 4319/4885DAO 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.